نتایج جستجو برای: mibg therapy

تعداد نتایج: 654606  

Journal: :Pediatric blood & cancer 2005
James P Howard John M Maris Leslie S Kersun John P Huberty Su-Chun Cheng Randall A Hawkins Katherine K Matthay

BACKGROUND (131)I Metaiodobenzylguanidine ((131)I-MIBG) is an effective targeted radiotherapeutic for neuroblastoma with response rates greater than 30% in refractory disease. Toxicity is mainly limited to myelosuppression. The aim of this study was to determine the response rate and hematologic toxicity of multiple infusions of (131)I-MIBG. PROCEDURE Patients received two to four infusions o...

2017
Libo Zhang Douglass C Vines Deborah A Scollard Trevor McKee Teesha Komal Milan Ganguly Trevor Do Bing Wu Natasha Alexander Reza Vali Amer Shammas Travis Besanger Sylvain Baruchel

Peptide-receptor imaging and therapy with radiolabeled somatostatin analogs such as 68Ga-DOTA-TATE and 177Lu-DOTA-TATE have become an effective treatment option for SSTR-positive neuroendocrine tumors. The purpose of this study was to evaluate the correlation of somatostatin receptor-2 (SSTR2) expression with 68Ga-DOTA-TATE uptake and 177Lu-DOTA-TATE therapy in neuroblastoma (NB) xenograft mode...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009
Keshan Satharasinghe Toby N Trahair Draga Barbaric Tracey A O'Brien Susan J Russell Richard J Cohn Glenn M Marshall David S Ziegler

TO THE EDITOR: Kushner et al investigate the most sensitive modality for early detection of relapse in patients with asymptomatic high-risk neuroblastoma who had previously achieved complete remission or very good partial remission. They demonstrate that iodine123 (I) metaiodobenzylguanidine (MIBG) scanning was the only positive surveillance scan in 27% of patients and conclude that IMIBG scann...

Journal: :Clinical oncology (Royal College of Radiologists (Great Britain)) 2012
K Y Gulenchyn X Yao S L Asa S Singh C Law

The purpose of this systematic review was to investigate the effects of therapeutic radiopharmaceuticals in patients with different types of advanced neuroendocrine tumour (NETs). A literature search was carried out in MEDLINE and EMBASE from January 1998 to November 2010. The Cochrane Library (to Issue 10, 2010) and the Standards and Guidelines Evidence Inventory of Cancer Guidelines, includin...

2014
David L Bushnell Mark T Madsen Thomas O’cdorisio Yusuf Menda Saima Muzahir Randi Ryan M Sue O’dorisio

BACKGROUND Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of the limits imposed on administered activity levels by radiation damage to normal tissues. The goa...

2013
Simone Maurea Giovanni Fiumara Teresa Pellegrino Emilia Zampella Roberta Assante Pierpaolo Mainenti Alberto Cuocolo

Malignant pheochromocytomas respond to chemotherapy with a reduction in tumor size and catecholamine secretion. We investigated the usefulness of molecular imaging with meta-iodobenzylguanidine (MIBG) for evaluating the effects of chemotherapy in patients with malignant pheochromocytoma. Six patients were studied before and after 6 ± 4 months of combination chemotherapy with cyclophosphamide, v...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012
Katherine K Matthay Brian Weiss Judith G Villablanca John M Maris Gregory A Yanik Steven G Dubois James Stubbs Susan Groshen Denice Tsao-Wei Randall Hawkins Hollie Jackson Fariba Goodarzian Heike Daldrup-Link Ashok Panigrahy Alexander Towbin Hiroyuki Shimada John Barrett Norman Lafrance John Babich

UNLABELLED (131)I-metaiodobenzylguanidine (MIBG) is specifically taken up in neuroblastoma, with a response rate of 20%-37% in relapsed disease. Nonradioactive carrier MIBG molecules inhibit uptake of (131)I-MIBG, theoretically resulting in less tumor radiation and increased risk of cardiovascular toxicity. Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-MIB...

Journal: :Annals of nuclear medicine 2005
Shinro Matsuo Ichiro Nakae Daisuke Masuda Tetsuya Matsumoto Minoru Horie

A 48-year-old male patient was admitted to our hospital with dyspnea accompanied by orthopnea. Chest x-rays showed a cardiothoracic ratio of 68% and pulmonary congestion. He was diagnosed with dilated cardiomyopathy. Beta-Blocker (carvedilol) therapy was initiated on Day 22 of the disease using a small initial dose. He was followed up based on BNP levels and MIBG scintigraphy. The H/M ratio and...

2012
Antonella Stefanelli Giorgio Treglia Alessandro Giordano

Iodine-123-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy is a nuclear medicine technique which describes the functional status of the cardiac sympathetic nervous system. It is well known that an autonomic dysfunction is present in heart failure setting as a neuronal uptake of norepinephrine is impaired in the failing myocardium. Reduction in sympathetic nervous function in the heart, measu...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012
Annette Sorensen Robert J Mairs Lynne Braidwood Craig Joyce Joe Conner Sally Pimlott Moira Brown Marie Boyd

UNLABELLED Oncolytic herpes viruses show promise for cancer treatment. However, it is unlikely that they will fulfill their therapeutic potential when used as monotherapies. An alternative strategy is to use these viruses not only as oncolytic agents but also as a delivery mechanism of therapeutic transgenes to enhance tumor cell killing. The herpes simplex virus 1 deletion mutant HSV1716 is a ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید